Cargando…

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma

More than half of patients with malignant mesothelioma show alterations in the BAP1 tumor-suppressor gene. Being a member of the Polycomb repressive deubiquitinating (PR-DUB) complex, BAP1 loss results in an altered epigenome, which may create new vulnerabilities that remain largely unknown. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, Gaurav Kumar, Landman, Nick, Neikes, Hannah K., Hulsman, Danielle, Lieftink, Cor, Beijersbergen, Roderick, Kolluri, Krishna Kalyan, Janes, Sam M., Vermeulen, Michiel, Badhai, Jitendra, van Lohuizen, Maarten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975229/ https://www.ncbi.nlm.nih.gov/pubmed/36657447 http://dx.doi.org/10.1016/j.xcrm.2022.100915

Ejemplares similares

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
por: Badhai, Jitendra, et al.
Publicado: (2020)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
por: Kolluri, Krishna Kalyan, et al.
Publicado: (2018)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
por: Schepers, Arnout, et al.
Publicado: (2021)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

Large‐scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma
por: De Rienzo, Assunta, et al.
Publicado: (2020)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation
por: Kostova, Elena B., et al.
Publicado: (2015)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma
por: Amelio, Ivano
Publicado: (2017)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2023)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

Inducing and exploiting vulnerabilities for the treatment of liver cancer
por: Wang, Cun, et al.
Publicado: (2019)

The RECQL helicase prevents replication fork collapse during replication stress
por: Benedict, Bente, et al.
Publicado: (2020)

High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells
por: Tuijnenburg, Paul, et al.
Publicado: (2019)

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
por: Barnett, Sarah E., et al.
Publicado: (2023)

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13
por: Martínez-Fernández, Carmen, et al.
Publicado: (2023)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

BAP1 promotes osteoclast function by metabolic reprogramming
por: Rohatgi, Nidhi, et al.
Publicado: (2023)

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
por: Andrici, Juliana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g1klsodrq8ni7ftri1kd995lsf